Mytulip (Chlormadinone Acetate, Ethinylestradiol)

• Mytulip, a combined oral contraceptive, is indicated for hormonal regulation to prevent pregnancy.
• Prevention of pregnancy: provides reliable contraceptive protection by inhibiting ovulation and inducing cervical mucus and endometrial changes that prevent fertilisation and implantation.

• Mytulip combines chlormadinone acetate, a progestogenic agent, with ethinylestradiol, a synthetic estrogen. The estrogen component suppresses the hypothalamic‑pituitary‑ovarian axis, reducing follicle‑stimulating hormone release, while the progestogen further inhibits luteinising hormone surge, preventing ovulation. Both hormones also thicken cervical mucus and modify the endometrium, creating an environment hostile to sperm penetration and implantation.

Mytulip may cause a range of adverse reactions. Common side effects are usually mild and transient, while serious or rare events require immediate medical attention.

Common Side Effects

• Nausea: mild stomach upset that often resolves with continued use.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Headache: mild to moderate headache episodes.
• Irregular vaginal bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects

• Blood clots (deep‑vein thrombosis, pulmonary embolism): sudden leg pain, swelling, or shortness of breath.
• Severe hypertension: markedly elevated blood pressure, headache, or visual changes.
• Liver disorders (cholestatic jaundice): yellowing of skin or eyes, dark urine, itching.

Before prescribing Mytulip, clinicians should evaluate several safety considerations.

• Contraindicated in pregnancy: product is category X and must not be used by pregnant women.
• History of thromboembolic disease: avoid due to increased clotting risk.
• Uncontrolled hypertension: assess blood pressure and treat before initiation.
• Estrogen‑sensitive tumors: contraindicated in known or suspected breast or endometrial cancer.
• Smoking in women over 35 years: heightened cardiovascular risk; advise cessation.
• Store at room temperature below 25°C: keep in the original packaging, protect from moisture and light.

Mytulip can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive efficacy.
• Rifampin or rifabutin: decrease hormone levels, increasing risk of unintended pregnancy.
• Protease inhibitor ritonavir: may raise estrogen concentrations, heightening side‑effect risk.

Moderate Interactions (Monitor Closely)

• Broad‑spectrum antibiotics (e.g., tetracycline, fluoroquinolones): possible modest reduction in contraceptive effect.
• St. John’s wort: may lower hormone levels, requiring additional contraceptive measures.
• Selective serotonin reuptake inhibitors: may increase incidence of mood‑related side effects.